eng ita
  • Harnessing drug resistance: development of innovative drugs against bacterial and parasite infections and against microbial drug resistance.

    The core research groups represented within NatSynDrugs have been brought together based on international reputation in microbial infection research. Each group contributes complementary skills to the Platform to facilitate a complete drug development programme. NatSynDrugs aims to realize the combined potential of the core groups involved who have the expertise in:

    1. isolation and characterization of new natural products
    2. rational design, based on innovative methodologies, of novel synthetic drug candidates
    3. managing standard organic chemistry or combichem to synthesize new active chemical entities
    4. pharmacological investigation and development of the selected drugable compounds.

    ESKAPE Pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species) are antibiotic-resistant bacteria that cause most hospital infections and are among the biggest threats infectious diseases. Patients with infections caused by drug-resistant bacteria are generally at increased risk of worse clinical outcomes and death, and consume more healthcare resources than patients infected with the same bacteria that are not resistant.

    Malaria is one of the main causes of death in the world, afflicting the populations of at least 102 countries, with about two billion persons at risk of infection in tropical and subtropical areas. Today the infection is mainly caused by resistant strains to known therapeutic tools such as chloroquine. Effective and innovative, low cost drugs that can be used for long periods are urgently needed to delay the onset of resistance, rendering the therapeutic treatment more accessible and spreading it to countries linked to poverty.
    Leishmania. According to the WHO, leishmaniasis is endemic in 88 countries, 82% of which are developing countries. Currently, 15 million people are thought to be infected with Leishmania.

    Tuberculosis. Tuberculosis, a disease which man has been fighting for centuries, is back in full swing. TB kills more adults than any other infectious disease. In 2012, there were about 450 000 new cases of multidrug-resistant tuberculosis (MDR-TB).

Headquarters: via Banchi di Sotto, 55 - 53100 Siena ITALY
tel. +39 0577.234172 - +39 0577.234297 - fax. +39 0577.234333 - e-mail:info@natsyndrugs.com